Midomafetamine for alcoholism

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 13 Jul 2023: Trial registered, NCT05943665
  2. 6 Feb 2024: Trial started, NCT05943665
  3. 12 Aug 2025: Trial registered, NCT07118839
  4. 18 May 2026: Trial started, NCT07118839

The trials

NCT05943665: MDMA for AUD/PTSD Comorbidity

State
Completed
Phase
Phase 2
People
22 taking part
Started
6 Feb 2024
Primary completion
21 Jan 2026
Arms
MDMA-AT
Results
None posted
  1. 13 Jul 2023: Trial registered
  2. 6 Feb 2024: Trial started
  3. 30 Jan 2026: Trial completed

NCT07118839: MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder

State
Under way
Phase
Phase 2 and Phase 3
People
80 planned
Started
18 May 2026
Primary completion
1 May 2030
Arms
Full dose MDMA-Assisted Therapy
Results
None posted
  1. 12 Aug 2025: Trial registered
  2. 18 May 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as 3,4 Methylenedioxymethamphetamine, 3,4-Methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxymethamphetamine (125 mg), Active Dose 1 (125 mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Full Dose MDMA, Full Dose MDMA-assisted therapy (125 mg), Full dose MDMA-assisted therapy, Mdma, MDMA assisted psychotherapy, Open-Label Full Dose MDMA-assisted therapy (125 mg), methylenedioxymethamphetamine.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.